A randomized controlled trial for low-dose continuous Infusion of human atrial natriuretic peptide for high risk patients undergoing cardiac surgery

INTERVENTION: Perioperative administration of hANP (0.02ganma) Perioperative non‐administration of hANP CONDITION: myocardial infarction, angina PRIMARY OUTCOME: major adverse cardiovascular and cerebrovascular events (MACCE) SECONDARY OUTCOME: 1) postoperative death (early, late); 2) MACCE + hemodialysis (HD); 3) serum creatinine (sCr) and brain natriuretic peptide (BNP) levels at 1 week and 1 year postoperatively. INCLUSION CRITERIA: EuroScore>6 point On pump CABG Patients from whom informed consent was obtained